Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Financial Officer | February 01, 2021 | February 03, 2021 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Chief Financial Officer | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,295 |
Last balance in matching sequence
After 2021-02-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-02-01 · Exercise / conversion · Acquired 7,402 · Balance 68,697 F2: Includes 52,083 restricted stock units. Row 2 · 2021-02-01 · Sale · Disposed 7,402 · Balance 61,295 F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2: Includes 52,083 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 54,167 |
Reported balance
After 2021-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-01 · Exercise / conversion · Disposed 7,402 · Balance 54,167 F3: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
F2: Includes 52,083 restricted stock units.
F3: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
SpyGlass Pharma, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-05 | Direct | 17,500 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 17,500 · Balance 17,500 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date March 26, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
1 source rowRow 1 · 2024-04-05 · Other · Disposed 3,038 · Balance 0 F1: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on March 26, 2024. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2033-11-30 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 450,000 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F3: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on March 26, 2024.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F3: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,159 | $10.05 | $31,747.95 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 667 | $20.00 | $13,340.00 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,513 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,000 | $19.31 | $57,926.40 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,180 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.04 to $19.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 1,995 shares acquired on May 15, 2019 pursuant to Issuer's employee stock purchase plan. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,000 | $14.92 | $44,762.10 |
DisclosureSEC source: 0000899243-19-008784 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,185 F1 · price: The transaction was executed in multiple trades in prices ranging from $14.91 to $14.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-001203 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2029-01-11 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 6,297 | $12.37 | $77,893.89 |
DisclosureSEC source: 0000899243-19-001203 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,185 F1 · balance_after: Includes 1,278 shares acquired on November 15, 2018, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 16,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001203 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,482 F1 · balance_after: Includes 1,278 shares acquired on November 15, 2018, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 740 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-18-025185 · doc4.xml · derivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,741 Underlying: Common Stock · 740 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 740 | $13.50 | $9,990.00 |
DisclosureSEC source: 0000899243-18-025185 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 9,291 | $18.56 | $172,471.62 |
DisclosureSEC source: 0000899243-18-020572 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $18.20 to $18.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 3,112 shares acquired on May 15, 2018 pursuant to Issuer's employee stock purchase plan. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002885 · doc4.xml · derivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 6,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029149 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,958 Read SEC document |
| August 06, 2017 Filed Aug 8, 2017 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-17-019841 · doc4.xml · derivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2027-08-06 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to (i) fifty percent (50%) of the total number of shares subject to the option after one year measured from August 1, 2017 (the "Vesting Commencement Date"), (ii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the eighteen (18) month anniversary of the Vesting Commencement Date and (iii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the two year anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-17-002094 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,481 Underlying: Common Stock · 3,900 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,900 | $27.00 | $105,300.00 |
DisclosureSEC source: 0000899243-17-002094 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,900 | $13.50 | $52,650.00 |
DisclosureSEC source: 0000899243-17-002094 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 667 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-16-036028 · doc4.xml · derivative · entry 5 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,381 Underlying: Common Stock · 667 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 667 | $13.50 | $9,004.50 |
DisclosureSEC source: 0000899243-16-036028 · doc4.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-16-036028 · doc4.xml · derivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,048 Underlying: Common Stock · 3,900 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,900 | $28.30 | $110,364.93 |
DisclosureSEC source: 0000899243-16-036028 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.75 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,900 | $13.50 | $52,650.00 |
DisclosureSEC source: 0000899243-16-036028 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-16-034104 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,948 Underlying: Common Stock · 3,900 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,900 | $28.19 | $109,955.04 |
DisclosureSEC source: 0000899243-16-034104 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.95 to $28.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,900 | $13.50 | $52,650.00 |
DisclosureSEC source: 0000899243-16-034104 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-16-032269 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,848 Underlying: Common Stock · 3,900 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,900 | $30.62 | $119,402.79 |
DisclosureSEC source: 0000899243-16-032269 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.93 to $30.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,900 | $13.50 | $52,650.00 |
DisclosureSEC source: 0000899243-16-032269 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-16-030224 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,748 Underlying: Common Stock · 3,900 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,900 | $29.88 | $116,549.94 |
DisclosureSEC source: 0000899243-16-030224 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.59 to $30.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,900 | $13.50 | $52,650.00 |
DisclosureSEC source: 0000899243-16-030224 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.